Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 190 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cerebrospinal Fluid Clear all

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: CSF Diversion; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer, Non-Small Cell Lung Cancer
Interventions: CNSide; Device
Lead sponsor: Biocept, Inc.; Industry
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Stanford, California • Chicago, Illinois • Dallas, Texas + 1 more

Conditions: Alzheimer's Disease, Dementia
Interventions: Placebo, donepezil (Aricept); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: CSF Flow Through the Shunt of a Hydrocephalus Patient
Interventions: ShuntCheck; Device
Lead sponsor: NeuroDx Development; Industry
Eligibility: Up to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer Disease
Interventions: GSI-953, Placebo; Drug · Other
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Glendale, California

Conditions: Late Infantile Neuronal Ceroid Lipofuscinosis, Batten Disease
Interventions: Group 1; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 2 Years to 8 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer's Disease
Interventions: CNP520, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years to 80 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Glendale, California • Long Beach, California • Miami, Florida + 1 more

Conditions: Neuro-Degenerative Disease, Cancer
Interventions: Clonidine Pill; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Neoplasms
Interventions: AVI-4126 Injection (RESTEN-NG®); Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: ABT-957, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Cypress, California • Orlando, Florida • The Villages, Florida + 6 more

Conditions: Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions: Not listed
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years to 89 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Subarachnoid Hemorrhage
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cerebral Palsy, Multiple Sclerosis, Traumatic Brain Injury, Spinal Cord Injury
Interventions: Not listed
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 12 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Indianapolis, Indiana • Philadelphia, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions: Not listed
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years to 89 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hydrocephalus
Interventions: Thermal Anisotropy Measurement Device; Device
Lead sponsor: Rhaeos, Inc.; Industry
Eligibility: Not listed
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Oakland, California • San Francisco, California • Chicago, Illinois

Conditions: Leptomeningeal Metastasis
Interventions: Not listed
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Alzheimer Disease
Interventions: Simvastatin, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 35 Years to 69 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Parkinson Disease
Interventions: Intracerebral Infusion of Autologous Cerebral Spinal Fluid; Device
Lead sponsor: Jeff Elias, MD; Other
Eligibility: 30 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions: Not listed
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years to 90 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Post-Hemorrhagic Hydrocephalus
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Radiologically Isolated Syndrome, Multiple Sclerosis
Interventions: Observational; Other
Lead sponsor: Centre Hospitalier Universitaire de Nīmes; Other
Eligibility: Not listed
Enrollment: 320 participants
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer, Leptomeningeal Metastasis
Interventions: OncoCEE; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Angelman Syndrome, Chromosome 15q Duplication (dup15q) Syndrome
Interventions: Lumbar Puncture, Blood Collection; Procedure
Lead sponsor: Biogen; Industry
Eligibility: Up to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Encephalitis
Interventions: AVI-4065 Injection; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Tacoma, Washington

Search by objective public record fields.

Cerebrospinal Fluid (CSF) Drainage Study

A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide

Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid

Physician Preference Study of ShuntCheck - Madsen

Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients

Collection of Cerebrospinal Fluid in Healthy Children

Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

Feasibility of Administering Clonidine as a Pharmacological Challenge in Imaging Studies

Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid

Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment

Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population

Evaluation of Cerebral Spinal Fluid and Blood in Patients With Subarachnoid Hemorrhage

Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery

Pennsylvania Consortium: Clinical Database

Assessment of CSF Shunt Flow With Thermal Measurements A

Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)

Evaluating Simvastatin's Potential Role in Therapy

Convection Enhanced Delivery of CSF in DBS for Parkinson's

Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology

Cerebral Perfusion, Oxygenation, Electrical Activity

Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.

Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer

Angelman Syndrome (AS) Biomarker Study

Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid